期刊文献+

产超广谱β-内酰胺酶细菌感染的耐药性分析 被引量:12

Bacterial Infections that with Extended Spectrum β Lactamases(ESBLs) Production: Drug Resistance Analysis
下载PDF
导出
摘要 目的:了解产超广谱β-内酰胺酶(ESBLs)细菌感染的发生率及耐药特征,为临床用药提供参考。方法:对我院2001年~2004年分离出的大肠埃希菌和肺炎克雷伯菌进行ESBLs检测,比较各年感染的发生率,并采用K-B纸片法进行药敏试验。结果:产ESBLs的大肠埃希菌、肺炎克雷伯菌感染发生率呈逐年上升趋势;产ESBLs的大肠埃希菌、肺炎克雷伯菌对亚胺培南的耐药率最低,分别为1.9%、2.9%,其次是哌拉西林/他唑巴坦、阿米卡星,分别为26.2%、20.5%和33.6%、35.2%。结论:碳青酶烯类抗生素可作为产ESBLs细菌感染的首选药。 OBJECTIVE : To study the incidences and drug - resistance characteristics of bacteria infections that with ES- BLs production for references of clinical medication.METHODS: Escherichia coli and Klebsiella pneumoniae isolated from 2001to 2004 were subjected to ESBLs detection .The incidence of infection of each year was compared and the susceptibility test was performed by K - B paper disk method.RESULTS: Bacterial infection incidences caused by ESBLs - producing E.coli and Klebsiella pneumoniae increased year by year.Strains with ESBLs producution showed lower sensitivity to antibiotics than those without.E.coli and K.pneumoniae that with ESBLs productions showed the lowest drug resistance rates, which stood at 1.9% and 2.9%, respectively.Their drug resistances to piperacillin/tazobactam were 26.2% and 20.5%, respectively and 33.6% and 35.2%, respectively to amikacin.CONCLUSION: Carbapenem antibiotics are the optimal choice in the treatment of bacterial infections that with ESBLs production.
出处 《中国药房》 CAS CSCD 北大核心 2006年第6期445-446,共2页 China Pharmacy
关键词 超广谱Β-内酰胺酶 细菌 耐药性 抗菌药物 Extended - spectrum β - lactamases Bacteria Drug resistance Antibacterials
  • 相关文献

参考文献10

二级参考文献53

  • 1李洁,曾海涛,徐秀华.烧伤病房耐甲氧西林金黄色葡萄球菌的DNA重复序列PCR研究[J].中华烧伤杂志,2001,17(2):24-26. 被引量:6
  • 2[5]Bush K,Jscky GA,Medeiros A.A functional classification scheme for β-lactamase and its correlation with molecular structure[J].Antimicrob Agents Chemother,1995,39(6): 1211.
  • 3[1]Widmer AF. Infection control and prevention strategies in the ICU[J]. Int Care Med, 1994, 20(Suppl 4): S7-S11.
  • 4[3]Troillet N, Samore MH, Carmeli Y. Imipenem-resistant Pseudomonas aeruginosa: risk factors and antibiotic susceptibility patterns[J]. Clin Infect Dis, 1997, 25(12): 1094-1098.
  • 5[1]National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing[S]. Ninth information.NCCLS,1999.
  • 6[1]Jacoby GA,Mederiros AA. More extended-spectrum β-lactamases[J]. Antimicrob Agents Chemother,1991, 35(9):1697-1704.
  • 7[4]Sanders CC,Barry AL, Washington JA, et al. Detection of extended-spectrum β-lactamases-producing members of the family Enterobacteriaceae with the VITEK ESBLs test [J]. J Clin Microbiol, 1996,34(12): 2997-3001.
  • 8[5]Livermore DM. β-Lactamases in laboratory and clinical resistance [J]. J Clin Microbiol Rev, 1995, 8(3): 557-584.
  • 9[6]National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. Ninth informational supplement [S]. NCCLS, 1999.19: 36-75.
  • 10[9]Rasmussen BA, Bush K. Carbapenem-hydrolyzing β-lactamases [J]. Antimicrob Agents Chemother, 1997, 41(2): 223-232.

共引文献382

同被引文献65

引证文献12

二级引证文献99

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部